Paroxysmal atrial fibrillation caused by hypokalemia in a healthy donor who underwent PBSC apheresis

摘要

Tacrolimus, a heterocyclic macrolide immunosupressive agent that belongs to the calcineurin inhibitor class, works by blocking the production of IL-2, thereby inhibiting proliferation of antigen-specific T lymphocytes.1 It is estimated to be 50-200 times more potent than cyclosporin (CYA) and is now commonly used after allo-SCT to prevent GVHD. Although common adverse effects like hypertension, nephrotoxicity and hyperglycemia are manageable without drug discontinuation, serious adverse effects might require discontinuation and change to an immunosuppressive agent from a different class.1 Reported incidence of neurotoxicity from tacrolimus may be as high as 32%.